Anika Therapeutics, Inc. Repayments of Long-Term Debt
Anika Therapeutics, Inc. (ANIK) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2023-03-16
- Anika Therapeutics, Inc. repayments of long-term debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. repayments of long-term debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. repayments of long-term debt for the quarter ending 2020-12-31 was $25.00M.
- Anika Therapeutics, Inc. repayments of long-term debt for the quarter ending 2020-09-30 was $25.00M.
- Anika Therapeutics, Inc. repayments of long-term debt for fiscal 2022 was $0.00.
- Anika Therapeutics, Inc. repayments of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Anika Therapeutics, Inc. repayments of long-term debt for fiscal 2020 was $50.35M.
- Anika Therapeutics, Inc. repayments of long-term debt for fiscal 2019 was $0.00.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2020-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $50.00M derived: sum of 2 quarters · filed 2023-03-16 | $50.35M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $25.35M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $351.00K 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2021-04-26 | |||
| 2013-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $8.80M derived: sum of 2 quarters · filed 2016-03-10 | $9.20M derived: sum of 3 quarters · filed 2016-03-10 | $9.60M 10-K · filed 2016-03-10 |
| 2013-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $800.00K derived: sum of 2 quarters · filed 2014-11-06 | $1.20M 10-Q · filed 2014-11-06 | $1.60M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $800.00K 10-Q · filed 2014-08-04 | $1.20M derived: sum of 3 quarters · filed 2015-03-13 | $1.60M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $400.00K 10-Q · filed 2014-05-05 | $800.00K derived: sum of 2 quarters · filed 2015-03-13 | $1.20M derived: sum of 3 quarters · filed 2015-03-13 | $1.60M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $800.00K derived: sum of 2 quarters · filed 2015-03-13 | $1.20M derived: sum of 3 quarters · filed 2015-03-13 | $1.60M 10-K · filed 2015-03-13 |
| 2012-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $800.00K derived: sum of 2 quarters · filed 2013-11-05 | $1.20M 10-Q · filed 2013-11-05 | $1.60M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $800.00K 10-Q · filed 2013-08-06 | $1.20M derived: sum of 3 quarters · filed 2014-03-13 | $1.60M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-03-31 | $400.00K 10-Q · filed 2013-05-06 | $800.00K derived: sum of 2 quarters · filed 2014-03-13 | $1.20M derived: sum of 3 quarters · filed 2014-03-13 | $1.60M derived: sum of 4 quarters · filed 2014-03-13 |
| 2011-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $800.00K derived: sum of 2 quarters · filed 2014-03-13 | $1.20M derived: sum of 3 quarters · filed 2014-03-13 | $1.60M 10-K · filed 2014-03-13 |
| 2011-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $800.00K derived: sum of 2 quarters · filed 2012-11-08 | $1.20M 10-Q · filed 2012-11-08 | $1.60M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $800.00K 10-Q · filed 2012-08-07 | $1.20M derived: sum of 3 quarters · filed 2013-03-14 | $1.60M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-03-31 | $400.00K 10-Q · filed 2012-05-07 | $800.00K derived: sum of 2 quarters · filed 2013-03-14 | $1.20M derived: sum of 3 quarters · filed 2013-03-14 | |
| 2010-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | $800.00K derived: sum of 2 quarters · filed 2013-03-14 | $1.60M 10-K · filed 2013-03-14 | |
| 2010-09-30 | $400.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-04 | $1.20M 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $800.00K 10-Q/A · filed 2011-08-10 | |||
| 2009-12-31 | $1.60M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |